<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The European Society of Cardiology has recently published an update on the antiarrhythmic treatment of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The recommendations emphasize the safety aspect of the treatment </plain></SENT>
<SENT sid="2" pm="."><plain>The first line antiarrhythmic medication should be chosen on the basis on a safer although possibly less efficacious profile while more potent but possibly more toxic agents should be reserved in case of treatment failure </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, the use of <z:chebi fb="0" ids="2663">amiodarone</z:chebi> is reserved for cases who have failed treatment with class I agents or sotalol or have contraindications for their use </plain></SENT>
<SENT sid="4" pm="."><plain>The recommendations put <z:chebi fb="0" ids="50659">dronedarone</z:chebi>, a new antiarrhythmic drug, as a first line treatment in the new therapeutic algorithm based on its safety profile and positive impact on morbi-mortality </plain></SENT>
<SENT sid="5" pm="."><plain>This article presents the main properties of <z:chebi fb="0" ids="50659">dronedarone</z:chebi> based on the published results of randomized trials </plain></SENT>
</text></document>